GENESIS-PHARMA
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and as monotherapy treatment for certain patients with recurrent or metastatic cervical cancer.
The two companies will work to seamlessly complete the transition of all relevant commercialization activities by the second quarter of 2024.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “For more than 20 years our company has been committed to ensure patient access to innovative therapies for serious diseases in several European markets building upon a constantly growing network of partners that includes leading global biopharma companies. It is thus our honor to initiate a new agreement with Regeneron, a pioneering company committed to cutting-edge science, that further enhances our long-term expertise and focus on medicines targeting difficult-to-treat cancers.”
About GENESIS Pharma: GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies.
For more information, please visit www.genesispharmagroup.com or follow GENESIS Pharma on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301136761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit18.11.2025 21:48:00 CET | Press release
At today’s Franco-German Summit on Digital Sovereignty in Berlin, Owkin, together with leading academic partners Gustave Roussy (France) and Charité Comprehensive Cancer Center (Germany), announced a landmark initiative to build the first pan-European agentic infrastructure to make biological data AI-ready, as a key step towards biological super intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118529021/en/ Thomas Clozel (CEO of Owkin) joins Emmanuel Macron, Friedrich Merz and others at the Franco-German Digital Sovereignty Summit The project aims to develop and deploy modern AI methods to support biological research and drug development. An initial focus will be on supporting the harmonization and structuring of biomedical data across Europe to enhance scientific collaboration. It will combine agentic AI systems and cutting-edge biomedical data structuring, to power a new reasoning model capable of automating
Reply at Microsoft Ignite 2025: Showcasing AI Innovation, Copilot Experiences, and Intelligent Enterprise Solutions18.11.2025 21:30:00 CET | Press release
Reply [EXM, STAR: REY] is taking part in Microsoft Ignite 2025, a premier event for technology professionals and decision-makers hosted by Microsoft, held from November 18 to 21 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118836834/en/ A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. With more than 2,000 Microsoft certifications across its network of companies – including Business Elements Reply, Cluster Reply, Solidsoft Reply, Light Reply, Root16 Reply, Valorem Reply, WM Reply and Zest Reply – the group has achieved all six Microsoft Solutions Partner designations. This year, Reply is also celebrating two major h
ClickHouse Strengthens Collaboration with Microsoft through Microsoft OneLake Integration for Seamless Data Interoperability18.11.2025 21:00:00 CET | Press release
ClickHouse Inc., the company behind one of the world’s fastest and most popular real-time analytics databases, today announced the availability of a powerful new integration with Microsoft OneLake, the unified data lake of Microsoft Fabric. This integration enables organizations to harness the scale, governance, and simplicity of OneLake with the speed and flexibility of ClickHouse for real-time, large-scale analytical workloads. Learn more in our technical post. Expanding the ClickHouse-Microsoft collaboration Following the general availability of ClickHouse Cloud on Microsoft Azure, recent performance enhancements of ClickHouse on Azure Blob Storage, and a steady series of new capabilities, this integration with Microsoft OneLake marks the latest milestone in ClickHouse’s growing collaboration with Microsoft. This initiative reinforces ClickHouse’s commitment to deep interoperability across Microsoft’s data ecosystem. From Azure to Fabric, the goal is to enable real-time analytics wi
Spatial Announces the Release of 2026 1.0: Enhanced CAD Translation, Model Simplification and Mesh Preparation18.11.2025 20:53:00 CET | Press release
Streamline design, manufacturing, and simulation workflows with improved robustness and performance. Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced Release 2026 1.0 and updates across several product lines, reaffirming its commitment to providing innovative solutions. Release 2026 1.0 delivers major enhancements across Spatial’s SDKs, improving CAD translation, data preparation, and meshing workflows. 3D InterOp adds expanded PMI, MBD, and CAD format support, while Hidden Body Removal (HBR) now extends to Parasolid-based translations. Furthermore, both 3D ACIS Modeler and CGM Modeler offer various enhancements including the new Mesh Prep for ACIS to simplify the creation of meshes for simulation workflows. Together, these updates boost interoperability, automation, and overall efficiency from design to manufacturing and simulation. Enhancements include: 3D InterOpSOL
New RSA Agent for Admin Threats Now Generally Available in Microsoft Security Copilot18.11.2025 19:07:00 CET | Press release
RSA Security today announced the general availability of its RSA Advisor for Admin Threats agent in Microsoft Security Copilot. “AI is the force multiplier for defenders, and when partners bring their agentic innovation into the Security Copilot ecosystem, the impact is exponential. Together, we’re not just building tools—we’re creating a new era of intelligent, collaborative cyber defense.” - Vasu Jakkal, Corporate Vice President, Microsoft Security. “We accelerated development of the RSA Advisor for Admin Threats agent to give security leaders the essential AI capabilities they need to quickly detect and resolve high-risk activity or insider threats in RSA ID Plus for Microsoft tenants,” said RSA President, Chief Product and Strategy Officer Jim Taylor. “In a recent RSA survey of more than 2,100 global security leaders, agentic AI emerged as the top cybersecurity priority, and 91% said they plan to integrate AI into their tech stack. We’re working with Microsoft to meet customers’ de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom